Non-small cell lung carcinoma genotype(s)-EGFR Posts on Medivizor
Navigation Menu

Non-small cell lung carcinoma genotype(s)-EGFR Posts on Medivizor

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Posted by on Oct 31, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) first-line treatment and performance status in older patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The data showed that older patients with EGFR-mutated NSCLC who received EGFR-TKI first-line treatment with a...

Read More

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Does tyrosine kinase inhibitors therapy after surgery benefit patients with EGFR-mutant resected NSCLC?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy after surgery. The data showed that EGFR-TKI therapy after surgery significantly improved survival without disease progression in...

Read More

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Posted by on Jun 5, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness of EGFR-tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) in advanced non-small-cell lung cancer (NSCLC). The authors found that TKIs plus SBRT improved the survival without disease worsening for these patients.  Some background Lung cancer...

Read More

Is olmutinib effective in treating T790M-positive unresponsive non-small cell lung cancer?

Is olmutinib effective in treating T790M-positive unresponsive non-small cell lung cancer?

Posted by on Apr 3, 2021 in Lung cancer | 0 comments

In a nutshell This article looked at the use of olmutinib (Olita) in the treatment of T790M-positive non-small cell lung cancer (NSCLC) that was previously unresponsive to a tyrosine kinase inhibitor (TKI). The authors concluded that olmutinib had clinical activity and manageable side effects in these patients. Some background NSCLC accounts for...

Read More

Osimertinib in EGFR-positive non-small cell lung cancer spread to the brain or the layers surrounding the brain.

Osimertinib in EGFR-positive non-small cell lung cancer spread to the brain or the layers surrounding the brain.

Posted by on Oct 24, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of osimertinib (Tagrisso) in non-small cell lung cancer (NSCLC) that has spread to the brain of the layers of the brain (meninges). The authors concluded that osimertinib showed improved survival and had a good response rate in these patients. Some...

Read More

Looking for patients with metastatic lung cancer to trial a treatment combination

Looking for patients with metastatic lung cancer to trial a treatment combination

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell This trial is being carried out to assess whether osimertinib (Tagrisso) should be used alone or with chemotherapy for lung cancer and abnormalities (mutations) in the EGFR gene. The main outcome that will be measured in this trial is survival without progression of the disease. This trial will take place in New Jersey and New...

Read More

Is combined treatment with erlotinib and bevacizumab effective in non-small cell lung cancer?

Posted by on May 18, 2019 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....

Read More

Erlotinib in patients with non-small cell lung cancer

Posted by on Dec 11, 2018 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using the medication erlotinib (Tarceva) in patients with non-small cell lung cancer improved survival. The study found that using erlotinib was safe, and may reduce the need for radical surgery in patients with non-small cell lung cancer. Some background Epidermal growth factor receptor (EGFR) is...

Read More